INmune Bio

INMB

Valor de mercado US$ 43,6 mi

Collaboration combines INmune Bio's clinical research with QCi's  Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XPro Initial engagement marks QCi's first commercial customer in pharmaceutical and biotechnology markets, expanding the application of quantum computing to drug development BOCA RATON, Fla. and HOBOKEN, N.J.

BOCA RATON, FL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, is excited to announce its participation in the upcoming 2026 Maxim Growth Summit, taking place from October 12th to 14th at The Hard Rock Hotel NYC. This prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries.

Appointments strengthen rare-disease commercialization planning and strategic partnering capabilities as Ebstrocel™ advances toward potential commercialization BOCA RATON, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced the appointments of R.

The on-demand presentation will be available on September 11, 2026, at 7:00 A.M. (ET) BOCA RATON, Fla, Sept.

INmune Bio is significantly undervalued, with Ebstrocel for RDEB driving a compelling investment thesis amid regulatory alignment and a $67M market cap. Ebstrocel offers systemic itch reduction, differentiating it from competitors like KRYS's Vyjuvek, and is positioned for UK, EU, and US regulatory filings by early 2027. Regulatory milestones may include upcoming filings for approval, and the initiation of a confirmatory Phase 3 trial.

Orphan Drug Designation application and pre-MAA Scientific Advice package submitted for Ebstrocel™ in RDEB Filings support a planned EU MAA in Q1 2027; orphan designation, if granted and maintained through approval, may provide regulatory incentives and 10 years of market exclusivity

INmune Bio Inc. (INMB) Q2 2026 Earnings Call Transcript

INmune Bio NASDAQ: INMB outlined plans to file for conditional approval of its Ebstrocel cell therapy in the United Kingdom by the end of the third quarter or early in the fourth quarter of 2026, while reporting a narrower second-quarter net loss and cash runway into the second quarter of 2027.

Management to host conference call and webcast at 4:30 pm ET on that day BOCA RATON, Fla, July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced t that it will host a conference call on Thursday, August 6th, 2026 at 4:30pm EDT to discuss results for its quarter ended June 30, 2026 and to provide a corporate update.  Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.

BOCA RATON, Fla., July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that on July 30, 2026, it received a research and development cash rebate from Australia of approximately $4.2 million.  This rebate is in addition to approximately $0.4 million of rebate from the United Kingdom during June 2026.  After adjusting second-quarter operating cash flows to exclude the approximately $0.4 million rebate received during the quarter, the combined rebate proceeds exceeded the Company's net cash used in operating activities during the quarter.  The rebates strengthen the Company's balance sheet and extend its cash runway as INmune Bio advances CORDStrom™ (Ebstrocel™) toward regulatory filings.